company background image
ATHX

AthersysNasdaqCM:ATHX Stock Report

Market Cap

US$237.6m

7D

4.8%

1Y

-36.6%

Updated

02 Dec, 2021

Data

Company Financials +
ATHX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ATHX Stock Overview

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine.

Athersys Competitors

MiMedx Group

NasdaqCM:MDXG

US$768.2m

Longeveron

NasdaqCM:LGVN

US$390.6m

Lineage Cell Therapeutics

NYSEAM:LCTX

US$365.8m

American CryoStem

OTCPK:CRYO

US$47.7m

Price History & Performance

Summary of all time highs, changes and price drops for Athersys
Historical stock prices
Current Share PriceUS$1.09
52 Week HighUS$3.03
52 Week LowUS$0.92
Beta-1.61
1 Month Change-18.66%
3 Month Change-35.12%
1 Year Change-36.63%
3 Year Change-42.02%
5 Year Change-31.87%
Change since IPO-79.24%

Recent News & Updates

Nov 25

Athersys: COVID-ARDS Is The Company's Most Important Target

I covered Athersys' ischemic stroke trial earlier. The stock has fallen as a result of issues with this trial. However, Covid-induced ARDS is its most important indication, where it has market-leading positive data.

Aug 30

Athersys Shares Are Ready To Rumble Following Period Of Turmoil

Positive ARDS Results in Japan should lead to approval and revenues. Enrollment complete in 220 patient stroke study in Japan. Japan's progressive regenerative medicine approval regulations bode well for success. Athersys shares have not reflected the upside of recent developments.

Shareholder Returns

ATHXUS BiotechsUS Market
7D4.8%-1.4%-3.5%
1Y-36.6%1.8%19.4%

Return vs Industry: ATHX underperformed the US Biotechs industry which returned 2% over the past year.

Return vs Market: ATHX underperformed the US Market which returned 17.8% over the past year.

Price Volatility

Is ATHX's price volatile compared to industry and market?
ATHX volatility
ATHX Average Weekly Movement8.8%
Biotechs Industry Average Movement8.8%
Market Average Movement6.1%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.4%

Stable Share Price: ATHX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ATHX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199597BJ Lehmannhttps://www.athersys.com

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers.

Athersys Fundamentals Summary

How do Athersys's earnings and revenue compare to its market cap?
ATHX fundamental statistics
Market CapUS$237.59m
Earnings (TTM)-US$87.45m
Revenue (TTM)US$6.06m

42.3x

P/S Ratio

-2.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ATHX income statement (TTM)
RevenueUS$6.06m
Cost of RevenueUS$71.02m
Gross Profit-US$64.96m
ExpensesUS$22.49m
Earnings-US$87.45m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.37
Gross Margin-1,071.59%
Net Profit Margin-1,442.59%
Debt/Equity Ratio0%

How did ATHX perform over the long term?

See historical performance and comparison

Valuation

Is Athersys undervalued compared to its fair value and its price relative to the market?

8.74x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ATHX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ATHX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ATHX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ATHX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ATHX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATHX is overvalued based on its PB Ratio (8.7x) compared to the US Biotechs industry average (2.7x).


Future Growth

How is Athersys forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

1.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATHX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ATHX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ATHX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ATHX's revenue (70.7% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: ATHX's revenue (70.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ATHX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Athersys performed over the past 5 years?

-34.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATHX is currently unprofitable.

Growing Profit Margin: ATHX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ATHX is unprofitable, and losses have increased over the past 5 years at a rate of 34.9% per year.

Accelerating Growth: Unable to compare ATHX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATHX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: ATHX has a negative Return on Equity (-297.99%), as it is currently unprofitable.


Financial Health

How is Athersys's financial position?


Financial Position Analysis

Short Term Liabilities: ATHX's short term assets ($58.1M) exceed its short term liabilities ($27.7M).

Long Term Liabilities: ATHX's short term assets ($58.1M) exceed its long term liabilities ($15.1M).


Debt to Equity History and Analysis

Debt Level: ATHX is debt free.

Reducing Debt: ATHX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ATHX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ATHX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 32.3% each year


Dividend

What is Athersys's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ATHX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ATHX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ATHX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATHX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATHX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

BJ Lehmann (55 yo)

0.83

Tenure

US$1,661,378

Compensation

Mr. William Lehmann, also known as B.J., Jr., J.D., M.B.A, has been the President and Chief Operating Officer at Athersys, Inc., since June 2006 and also serves as its Interim Chief Executive Officer since...


CEO Compensation Analysis

Compensation vs Market: BJ's total compensation ($USD1.66M) is above average for companies of similar size in the US market ($USD1.13M).

Compensation vs Earnings: BJ's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ATHX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: ATHX's board of directors are considered experienced (7.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ATHX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19%.


Top Shareholders

Company Information

Athersys, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Athersys, Inc.
  • Ticker: ATHX
  • Exchange: NasdaqCM
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$237.588m
  • Shares outstanding: 235.24m
  • Website: https://www.athersys.com

Number of Employees


Location

  • Athersys, Inc.
  • 3201 Carnegie Avenue
  • Cleveland
  • Ohio
  • 44115-2634
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/02 23:29
End of Day Share Price2021/12/02 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.